Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009–2012

Preventive Medicine

Volumn 103, Issue , 2017, Pages 60-65

  Watson, Meg ^a   Soman, Ashwini ^b   Flagg, Elaine W ^c   Unger, Elizabeth ^d   Deapen, Dennis ^e   Chen, Vivien W ^f   Peres, Lauren C ^f   Copeland, Glenn ^g   Tucker, Thomas C ^h   Garnett, Erin ⁱ   Saraiya, Mona ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Northrup Grumman   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^e Los Angeles Cancer Surveillance Program   (United States)

^f LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^g Michigan Cancer Surveillance Program   (United States)

^h Kentucky Cancer Registry   (United States)

ⁱ Advanced Technical Logistics   (United States)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; HPV; HPV vaccines; Population based cancer registries

Indexed keywords

ADENOCARCINOMA IN SITU; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER REGISTRY; CANCER SCREENING; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; RACE; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; HEALTH SURVEY; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; REGISTER; STATISTICS AND NUMERICAL DATA; TRENDS; UTERINE CERVIX TUMOR; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POPULATION SURVEILLANCE; REGISTRIES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 85028703934     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2017.07.027     Document Type: Article

References (35)

1. [North] American Association of Central Cancer Registries n.d. Working group on pre-invasive cervical neoplasia and population-based cancer registries: final subcommittee report. [N]AACCR conference held 5–6 Apr 1993, Rockville, MD. Subsequently adopted by the [N]AACCR Executive Board May 1993 and amended November 1993.
2. Adegoke, O., Kulasingam, S., Virnig, B., Cervical cancer trends in the United States: a 35-year population-based analysis. J. Women's Health (Larchmt) 21:10 (2012), 1031–1037.
3. American Society for Colposcopy and Clinical Pathology, CAP-ASCCP Lower Anogenital Squamous Terminology (LAST) for HPV-Associated Lesions. Accessed on February 9 2016; Available from: http://www.asccp.org/Practice-Management/LAST-Project/LAST-Consensus-Recommendations-and-Resources, 2015.
4. Benard, V.B., Thomas, C.C., King, J., Massetti, G.M., Doria-Rose, V.P., Saraiya, M., et al. Vital signs: cervical cancer incidence, mortality, and screening - United States, 2007–2012. MMWR Morb. Mortal. Wkly Rep. 63:44 (2014), 1004–1009.
5. Castellsague, X., Diaz, M., De Sanjose, S., Munoz, N., Herrero, R., Franceschi, S., et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. JNCI Cancer Spectrum 98:5 (2006), 303–315.
6. Castle, P.E., Fetterman, B., Poitras, N., Lorey, T., Shaber, R., Kinney, W., Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet. Gynecol. 113:3 (2009), 595–600.
7. Centers for Disease C, Prevention, Cervical cancer screening among women aged 18–30 years - United States, 2000–2010. MMWR Morb. Mortal. Wkly Rep. 61:51–52 (2013), 1038–1042.
8. Centers for Disease Control and Prevention, Tobacco Control State Highlights. 2012.
9. Centers for Disease Control and Prevention, Cervical Cancer Screening Guidelines for Average-risk Women. Accessed on March 4 2016; Available from: http://www.cdc.gov/cancer/cervical/pdf/guidelines.pdf, 2013.
10. Centers for Disease Control and Prevention, Behavioral Risk Factor Surveillance System: prevalence data and data analysis tools. 2016 Available from: http://www.cdc.gov/brfss/data_tools.htm.
11. DeCew, A.E., Hadler, J.L., Daley, A.M., Niccolai, L., The prevalence of HPV associated cervical intraepithelial neoplasia in women under age 21: who will be missed under the new cervical cancer screening guidelines?. J. Pediatr. Adolesc. Gynecol. 26:6 (2013), 346–349.
12. Flagg, E.W., Schwartz, R., Weinstock, H., Prevalence of anogenital warts among participants in private health plans in the United States, 2003–2010: potential impact of human papillomavirus vaccination. Am. J. Public Health 103:8 (2013), 1428–1435.
13. Flagg, E.W., Datta, S.D., Saraiya, M., Unger, E.R., Peters, E., Cole, L., et al. Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009. Cancer Causes Control 25:5 (2014), 571–581.
14. Hariri, S., Johnson, M.L., Bennett, N.M., Bauer, H.M., Park, I.U., Schafer, S., et al. Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States. Cancer 121:16 (2015), 2775–2781.
15. Hariri, S., Markowitz, L.E., Bennett, N.M., Niccolai, L.M., Schafer, S., Bloch, K., et al. Monitoring effect of human papillomavirus vaccines in US population, emerging infections program, 2008-2012. Emerg. Infect. Dis. 21:9 (2015), 1557–1561.
16. Hariri, S., Bennett, N.M., Niccolai, L.M., Schafer, S., Park, I.U., Bloch, K.C., et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States – 2008–2012. Vaccine 33:13 (2015), 1608–1613.
17. Kyrgiou, M., Koliopoulos, G., Martin-Hirsch, P., Arbyn, M., Prendiville, W., Paraskevaidis, E., Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367:9509 (2006), 489–498.
18. Limmer, K., LoBiondo-Wood, G., Dains, J., Predictors of cervical cancer screening adherence in the United States: a systematic review. J. Adv. Pract. Oncol. 5:1 (2014), 31–41.
19. Markowitz, L.E., Dunne, E.F., Saraiya, M., Lawson, H.W., Chesson, H., Unger, E.R., et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and Reports: Morbidity and Mortality Weekly Report. Recommendations and Reports/centers for Disease Control. 56(RR-2), 2007, 1–24.
20. Markowitz, L.E., Hariri, S., Lin, C., Dunne, E.F., Steinau, M., McQuillan, G., et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis 208:3 (2013), 385–393.
21. Markowitz, L.E., Liu, G., Hariri, S., Steinau, M., Dunne, E.F., Unger, E.R., Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics 137:3 (2016), 1–9.
22. Moscicki, A.B., Schiffman, M., Burchell, A., Albero, G., Giuliano, A.R., Goodman, M.T., et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 30:Suppl. 5 (2012), F24–33.
23. Petrosky, E., Bocchini, J.A. Jr., Hariri, S., Chesson, H., Curtis, C.R., Saraiya, M., et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR. Morb. Mortal. Wkly Rep. 64:11 (2015), 300–304.
24. Potter, R.C., Flagg, E.W., Datta, S.D., Saraiya, M., Copeland, G., Monitoring the impact of human papillomavirus vaccines on high-grade pre-invasive cervical lesions: designing a framework of linked immunization information system and cancer registry data in Michigan. Vaccine 33:11 (2015), 1400–1405.
25. Roura, E., Castellsague, X., Pawlita, M., Travier, N., Waterboer, T., Margall, N., et al. Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort. Int. J. Cancer 135:2 (2014), 453–466.
26. Ryerson, A.B., Eheman, C.R., Altekruse, S.F., Ward, J.W., Jemal, A., Sherman, R.L., et al. Annual report to the nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer 122:9 (2016), 1312–1337.
27. Saraiya, M., Berkowitz, Z., Yabroff, K.R., Wideroff, L., Kobrin, S., Benard, V., Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?. Arch. Intern. Med. 170:11 (2010), 977–985.
28. Saraiya, M., Steben, M., Watson, M., Markowitz, L., Evolution of cervical cancer screening and prevention in United States and Canada: implications for public health practitioners and clinicians. Prev. Med. 57:5 (2013), 426–433.
29. Saraiya, M., Unger, E.R., Thompson, T.D., Lynch, C.F., Hernandez, B.Y., Lyu, C.W., et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J. Natl. Cancer Inst., 107(6), 2015, djv086.
30. The Bethesda System for reporting cervical/vaginal cytologic diagnoses, Report of the 1991 Bethesda Workshop. Am. J. Surg. Pathol. 16:9 (1992), 914–916.
31. Tiwari, R.C., Clegg, L.X., Zou, Z., Efficient interval estimation for age-adjusted cancer rates. Stat. Methods Med. Res. 15:6 (2006), 547–569.
32. Watson, M., Saraiya, M., Benard, V., Coughlin, S.S., Flowers, L., Cokkinides, V., et al. Burden of cervical cancer in the United States, 1998–2003. Cancer 113:10 Suppl (2008), 2855–2864.
33. Watson, M., Garnett, E., Cole, L., Schmidt, B., Chen, V.W., Stoyanoff, S., et al. Audit of case finding completeness and accuracy in four registries collecting cervical cancer precursors, North American Association of Central Cancer Registries Annual Meeting; 2015; Charlotte NC, 2015.
34. Watson, M., Benard, V., King, J., Crawford, A., Saraiya, M., National assessment of HPV and Pap tests: changes in cervical cancer screening, National Health Interview Survey. Prev. Med. 100 (2017), 243–247.
35. Xu, F., Mawokomatanda, T., Flegel, D., Pierannunzi, C., Garvin, W., Chowdhury, P., et al. Surveillance for Certain Health Behaviors Among States and Selected Local Areas—Behavioral Risk Factor Surveillance System, United States, 2011. MMWR. Surveillance summaries: Morbidity and Mortality Weekly Report. Surveillance Summaries/CDC. 63(9), 2014, 1–149.